Vaxcyte, Inc. Contracts & Agreements
57 Contracts & Agreements
- Business Finance (18 contracts)
- Business Operations (12)
- Human Resources (11)
- Intellectual Property (2)
- Real Estate (6)
- Uncategorized (8)
- Form of Pre-Funded Warrant (Filed With SEC on September 6, 2024)
- Underwriting Agreement, dated September 4, 2024 (Filed With SEC on September 6, 2024)
- Form of Non. U.S. Restricted Stock Unit Grant Notice (2020 Equity Incentive Plan) (Filed With SEC on February 27, 2024)
- Form of Non-U.S. Stock Option Grant Notice and Stock Option Agreement (2020 Equity Incentive Plan) (Filed With SEC on February 27, 2024)
- First Amendment to Lease Agreement by and between the Registrant and ARE-San Francisco No. 63, LLC, dated October 17, 2023 (Filed With SEC on February 27, 2024)
- First Amendment to License Agreement by and between the Registrant and The Regents of the University of California, represented by its San Diego campus, dated August 16, 2019 (Filed With SEC on February 27, 2024)
- Manufacturing Rights Agreement by and between the Registrant and Sutro Biopharma, Inc., dated November 21, 2023 (Filed With SEC on February 27, 2024)
- Commercial Manufacturing and Supply Agreement by and between the Registrant and Lonza Ltd., dated October 13, 2023 (Filed With SEC on February 27, 2024)
- Master Services Agreement for Drug Product Development and Manufacturing between Registrant and Lonza Ltd., dated March 22, 2022, as amended (Filed With SEC on February 27, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on January 31, 2024)
- Underwriting Agreement, dated January 30, 2024 (Filed With SEC on January 31, 2024)
- Assignment and Assumption of Lease Agreement by and between the Registrant and Codexis, Inc., dated September 1, 2023 (Filed With SEC on November 6, 2023)
- Consent to Assignment and First Amendment by and among ARE-San Francisco No. 63, LLC, Codexis, Inc. and the Registrant, dated September 6, 2023 (Filed With SEC on November 6, 2023)
- Third Amendment to Amended and Restated SutroVax Agreement by and between Sutro Biopharma, Inc. and the Registrant, dated September 28, 2023 (Filed With SEC on November 6, 2023)
- Form of Stock Option Grant Notice and Stock Option Agreement (Filed With SEC on August 8, 2023)
- Vaxcyte, Inc. 2020 Equity Incentive Plan (Filed With SEC on August 8, 2023)
- Form of Pre-Funded Warrant (Filed With SEC on April 20, 2023)
- Underwriting Agreement, dated April 18, 2023 (Filed With SEC on April 20, 2023)
- Amendment No. 1 to Sales Agreement, dated February 27, 2023, by and between Vaxcyte, Inc. and Jefferies LLC (Filed With SEC on February 27, 2023)
- Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd., dated October 21, 2016, as amended (Filed With SEC on November 7, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on October 27, 2022)
- Underwriting Agreement, dated October 25, 2022 (Filed With SEC on October 27, 2022)
- Master Services Agreement for Drug Product Development and Manufacturing between the Registrant and Lonza Ltd., dated March 22, 2022, as amended (Filed With SEC on August 8, 2022)
- Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd., dated October 21, 2016, as amended (Filed With SEC on August 8, 2022)
- Form of Restricted Stock Unit Grant Notice (Filed With SEC on May 9, 2022)
- Offer Letter entered into by and between the Registrant and Mikhail Eydelman, dated March 4, 2022 (Filed With SEC on May 9, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on January 13, 2022)
- Underwriting Agreement, dated January 12, 2022 (Filed With SEC on January 13, 2022)
- Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd., dated October 21, 2016, as amended (Filed With SEC on November 10, 2021)
- Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd, dated October 21, 2016, as amended (Filed With SEC on May 11, 2021)
- Description of Capital Stock (Filed With SEC on March 29, 2021)
- Lease Agreement by and between the Company and ARE-San Francisco No. 63, LLC, dated as of January 21, 2021 (Filed With SEC on January 25, 2021)
- Vaxcyte, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on June 8, 2020)
- Vaxcyte, Inc. 2020 Equity Incentive Plan and forms of agreements thereunder (Filed With SEC on June 8, 2020)
- Form of common stock certificate of the Registrant (Filed With SEC on June 8, 2020)
- Form of Underwriting Agreement (Filed With SEC on June 8, 2020)
- Offer Letter entered into by and between the Registrant and Andrew Guggenhime, dated April 16, 2020 (Filed With SEC on May 22, 2020)
- Vaxcyte, Inc. Amended and Restated 2014 Equity Incentive Plan and forms of agreements thereunder (Filed With SEC on May 22, 2020)
- Offer Letter entered into by and between the Registrant and Jane Wright-Mitchell, dated December 6, 2018 (Filed With SEC on May 22, 2020)
- Executive Employment Agreement entered into by and between the Registrant and Jim Wassil, dated November 15, 2019 (Filed With SEC on May 22, 2020)
- Separation Agreement and Release entered into by and between the Registrant and Elaine Sun, dated December 17, 2019 (Filed With SEC on May 22, 2020)
- Executive Employment Agreement entered into by and between the Registrant and Elaine Sun, dated January 1, 2017 (Filed With SEC on May 22, 2020)
- Offer Letter entered into by and between the Registrant and Paul Sauer, dated April 12, 2016 (Filed With SEC on May 22, 2020)
- Executive Employment Agreement entered into by and between the Registrant and Jeff Fairman, dated January 21, 2016 (Filed With SEC on May 22, 2020)
- Executive Employment Agreement entered into by and between the Registrant and Grant Pickering, dated January 21, 2016 (Filed With SEC on May 22, 2020)
- Form of Indemnification Agreement to be entered into by and between the Registrant and each director and executive officer (Filed With SEC on May 22, 2020)
- Amended and Restated Investors Rights Agreement by and among the Registrant and certain of its stockholders, dated March 20, 2020 (Filed With SEC on May 22, 2020)
- Form of Executive Change in Control and Severance Agreement to be entered into by and between the Registrant and each eligible employee (Filed With SEC on May 22, 2020)
- Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd, dated October 29, 2018 (Filed With SEC on May 22, 2020)
- Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd, dated October 21, 2016, as amended (Filed With SEC on May 22, 2020)
- Letter Agreement by and between the Registrant and Lonza Ltd, dated June 19, 2018 (Filed With SEC on May 22, 2020)
- Amended and Restated SutroVax Agreement by and between the Registrant and Sutro Biopharma, Inc., dated October 12, 2015, as amended (Filed With SEC on May 22, 2020)
- Supply Agreement by and between the Registrant and Sutro Biopharma, Inc., dated May 29, 2018 (Filed With SEC on May 22, 2020)
- License Agreement by and between the Registrant and The Regents of the University of California, represented by its San Diego campus, dated February 4, 2019 (Filed With SEC on May 22, 2020)
- Lease Agreement by and among the Registrant, Grey Peak Fork, LLC and Grey Peak Fork, Series A, LLC, dated July 22, 2016 (Filed With SEC on May 22, 2020)
- Assignment and Assumption of Lease and Consent of Lessor by and among the Registrant, Orchard Therapeutics North America and Rakesh Kumar and Premila Kumar Revocable Family Trust,... (Filed With SEC on May 22, 2020)
- Third Addendum to Standard Multi-Tenant Office Lease by and between the Registrant and Rakesh Kumar and Premila Kumar Revocable Family Trust, dated July 1, 2019 (Filed With SEC on May 22, 2020)
